Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d3520e1eac4050a6f50d7e06e6c3fe5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00115 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
filingDate |
2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_559faa553b7c9044abc6dc9611188f04 |
publicationDate |
2011-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2011027303-A1 |
titleOfInvention |
Partial peptide of survivin presented on mhc class ii molecule and use therof |
abstract |
The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a Th1 cell which is a CD4-positive T cell specific to Survivin; and use of the tumor antigen. Specifically disclosed is a polypeptide which comprises an amino acid sequence depicted in SEQ ID NO:17 or the like and has an activity to cause the production of a cytokine by a Th cell that is a cell specific to Survivin. The peptide can induce a Th cell that is specific to Survivin and can cause the production of a cytokine by the Sur/Th cell when the peptide is incubated together with an antigen-presenting cell and a CD4-positive T cell. |
priorityDate |
2008-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |